July 8, 2012
. .
Tofacitinib is the first in a new class of immunosuppressive agents that inhibit janus kinase, an important transcription factor. This randomized-controlled trial compared tofacitinib to cyclosporine in renal transplant patients. Tofacitinib showed lower rates of acute rejection and chronic changes on biopsy, with better renal function compared to a cyclosporine-based regimen. On the other hand, […]
Comments Off on Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year
Posted in Renal Transplantation
July 8, 2012
. .
Donation after cardiac death (DCD) donors have become an important source of organs, but the rates of delayed graft function (DGF) remains high. Erythropoietin may protect against schema-reperfusion injury. In this randomized controlled trial, erythropoietin or placebo was given to recipients of DCD kidneys. There was no difference in DGF rates, acute rejection, or renal […]
Comments Off on Randomized Trial of Short-Course High-Dose Erythropoietin in Donation After Cardiac Death Kidney Transplant Recipients
Posted in Renal Transplantation
April 5, 2012
. .
In the last few years, the tacrolimus and mycophenolic acid has become the most popular therapy used in renal transplant, rather than the older cyclosporine and azathioprine combination. These authors conducted a randomized controlled trial to see whether the use of lymphocyte-depleting induction therapy would give equivalent results between these two drug regimens. In fact, […]
Comments Off on A Randomized Trial With Steroids and Antithymocyte Globulins Comparing Cyclosporine/Azathioprine Versus Tacrolimus/Mycophenolate Mofetil (CATM2) in Renal Transplantation
Posted in Renal Transplantation
Recent Comments